hydroxychloroquine has been researched along with moxifloxacin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
| Evavold, C; Kersh, GJ; Smith, CB | 1 |
| Cao, J; Fan, L; He, F; Hu, K; Lei, M; Luo, Q; Qin, S; Shao, X; Yang, L; Yu, N | 1 |
| Eid, M; El-Sayed, A; Elmansi, HM; Shalan, S | 1 |
2 review(s) available for hydroxychloroquine and moxifloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lopinavir; Lung; Lupus Erythematosus, Systemic; Moxifloxacin; Mycophenolic Acid; Pandemics; Pneumonia, Viral; Prednisone; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
4 other study(ies) available for hydroxychloroquine and moxifloxacin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |
The Effect of pH on Antibiotic Efficacy against Coxiella burnetii in Axenic Media.
Topics: Anti-Bacterial Agents; Axenic Culture; Coxiella burnetii; Culture Media; Doxycycline; Hydrogen-Ion Concentration; Hydroxychloroquine; Microbial Sensitivity Tests; Moxifloxacin; Rifampin | 2019 |
Validated spectrofluorimetric assay of two co-administered drug mixtures containing hydroxychloroquine with either moxifloxacin or ofloxacin as a drug regimen for hospital-acquired pneumonia in patients with COVID-19.
Topics: Anti-Bacterial Agents; COVID-19; COVID-19 Drug Treatment; Hospitals; Humans; Hydroxychloroquine; Moxifloxacin; Ofloxacin; Pandemics; Spectrometry, Fluorescence | 2023 |